End-to-end partnership
Kindeva (pronounced Kin-dev-uh) is led by industry experts and offers a complete range of capabilities and technologies with unparalleled dedication and flexibility. As a leading CDMO, we partner with you to advance complex drug product programs through our integrated, end-to-end capabilities.
As a leading CDMO, we partner with you to advance complex drug product programs through our integrated, end-to-end capabilities.
-
Formulation
- Assess feasibility of delivering the drug
- Develop formulation
- Develop and refine the delivery system
-
Product development
- Finalize product design and complete method validation
- Characterize in vitro performance of drug product
- Design clinical plan
- Lead and support pilot and pivotal studies
- Develop and register data package with regulatory authorities
-
Scale up manufacturing
- Develop manufacturing process at desired scale
- Support clinical trials and regulatory data package
- Demonstrate process performance through process validation
-
Commercial manufacturing
- Enact product’s control strategy
- Establish quality agreement with client
- Maintain process performance
- Assure continued compliance to evolving regulatory standards
Full-service innovation
At Kindeva, our capabilities are as extensive as our decades of experience. We have the expertise and technologies to help you realize your vision—however complex.
We’re always ready for the next challenge.
Inhalation Drug Delivery
- pMDIs, DPIs
- Connected inhalers
- Nasal
Capabilities applied to...
Transdermal Drug Delivery
- Drug-in-adhesive systems
- Membrane systems
- Reservoir systems
- Gel patches
Capabilities applied to...
Intradermal Drug Delivery
- Solid microstructures (microneedles)
- Hollow microstructures (microneedles)
Capabilities applied to...
Global reach
Global Headquarters
- St. Paul, USA
State-of-the-Art R&D Facilities
- Loughborough, UK
- St. Paul, USA
cGMP Manufacturing Facilities
- Loughborough, UK
- Clitheroe, UK
- Northridge, USA
- St. Paul, USA
A legacy of firsts
Kindeva was built on decades of taking clients from promise to patent, launching life-changing products and solving any challenge—every time.
-
1846
William Riker founded the drug store that would become Riker Labs
-
1956
First metered dose inhaler (MDI)
-
1970
First drug-in-adhesive patch
-
1989
First breath-actuated inhaler
-
1994
First stand-alone 7-day drug-in-adhesive patch
-
1995
First CFC-free MDI
-
2008
First single-cycle FDA review
-
2010
First commercially available dose counter
-
2012
First CFC-free nasal MDI
-
2015
First bioequivalent alternative to combination asthma therapy in the UK
-
2016
Introduced the Intelligent Control Inhaler
First generic transdermal product for Kindeva
-
2018
First commercial solid microsystems agreement signed
-
2019
Supplied Phase III clinical study for Solid Microsystems Abaloparatide Program
Follow us
Stay current as we continue to launch Kindeva Drug Delivery. In the meantime, read some of the recent thought leadership from our team.
Abstract: Application of theoretical models to predict expansion chamber…
read more
The challenges of drug delivery and surging interest in microneedles
read more
The drivers of delivery and the need for smarter solutions
read more
Examining the intersection of drug delivery and development
read more